GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

In the first episode of The Deep End Podcast, we meet Jon Nelson, who shares why he volunteered to get brain implants for his relentless depression.

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... The drug is the first ketamine-based medicine approved to treat depression. Ketamine has long been seen as a potential ...

The use of ketamine to treat severe depression was approved in Singapore in October 2020, to be administered as a nasal spray together with oral anti-depressant therapy. Clinical trials have shown ...

approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent version of ketamine. Esketamine should ...

Vistagen , a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced ...

Intranasal (IN) delivery of medications is ... A study comparing IN midazolam to IV midazolam and ketamine showed increased efficacy and ease of titration with the IV-administered medications ...

Ketamine, when abused, can be tremendously harmful and addictive. Nevertheless, esketamine, a dissociative hallucinogen that is administered by nasal spray, can be beneficial within a clinical ...

Ketamine can trigger symptoms similar to those of schizophrenia, but it isn’t known to cause the disorder itself. Ketamine is gaining attention for its potential to treat depression and other ...